PolyPid (NASDAQ:PYPD) Issues Earnings Results, Beats Estimates By $0.03 EPS

PolyPid (NASDAQ:PYPD) released its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03, FiscalAI reports.

Here are the key takeaways from PolyPid’s conference call:

• FDA accepted D-PLEX100’s NDA for filing with priority review and no filing-review issues identified; the PDUFA goal date is November 28, 2026.
• PolyPid signed an exclusive U.S. and Canadian commercialization agreement with Azurity, securing $30 million in upfront and near-term milestones, eligibility for more than $290 million in additional milestones, tiered royalties, and a transfer price on manufactured units.
• Azurity has begun launch preparations, including sales-force expansion, hospital contracting, medical affairs, and reimbursement efforts, with a commercial launch still expected in early 2027. The partnership will also fund label-expansion development in additional surgical indications.
• Management expects its cash resources, partnership proceeds, and potential future payments to fund operations into 2028, and said it has no immediate financing needs.
• PolyPid plans to submit D-PLEX100’s marketing authorization application to the European Medicines Agency in the third quarter of 2026 and is preparing for the FDA pre-approval manufacturing inspection; management reported productive regulatory discussions but approval remains subject to review.

PolyPid Stock Performance

PYPD stock traded down $0.12 during midday trading on Wednesday, hitting $4.61. 177,545 shares of the stock were exchanged, compared to its average volume of 127,560. The stock’s 50-day moving average price is $4.73 and its 200-day moving average price is $4.57. The stock has a market cap of $87.97 million, a price-to-earnings ratio of -2.41 and a beta of 1.41. PolyPid has a fifty-two week low of $3.06 and a fifty-two week high of $5.73.

Institutional Trading of PolyPid

Several large investors have recently modified their holdings of PYPD. BNP Paribas Financial Markets raised its stake in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of PolyPid during the 4th quarter worth about $44,000. Jane Street Group LLC purchased a new stake in shares of PolyPid during the fourth quarter worth about $66,000. ADAR1 Capital Management LLC purchased a new stake in shares of PolyPid during the fourth quarter worth about $451,000. Finally, XTX Topco Ltd raised its position in shares of PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after buying an additional 10,888 shares during the last quarter. 26.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PYPD has been the subject of several recent research reports. Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research note on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.33.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.